Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity

Published:2020-10-22 Issue: Volume:10 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Meyer Alina V.,Klein Diana,de Leve Simone,Szymonowicz Klaudia,Stuschke Martin,Robson Simon C.,Jendrossek Verena,Wirsdörfer Florian

Funder

Deutsche Forschungsgemeinschaft

Bundesministerium für Bildung und Forschung

Universität Duisburg-Essen

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference133 articles.

1. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410;Curran;J Natl Cancer Inst.,2011

2. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study;Bradley;Lancet Oncol.,2015

3. Radiotherapy dosing for locally advanced non-small cell lung carcinoma: “MTD” or “ALARA” ?;Ohri;Front Oncol.,2017

4. How the environment shapes cancer genomes;Pfeifer;Curr Opin Oncol.,2015

5. Improving the efficacy of chemoradiation with targeted agents;Morgan;Cancer Discov.,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Causal effect of immune cells on idiopathic pulmonary fibrosis: A mendelian randomization study;Heart & Lung;2024-11

2. MiR-378a-5p exerts a radiosensitizing effect on CRC through LRP8/β-catenin axis;Cancer Biology & Therapy;2024-02-22

3. CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells;Cell Reports Medicine;2023-08

4. CD39 – A bright target for cancer immunotherapy;Biomedicine & Pharmacotherapy;2022-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3